NCT02893358

Antihypertensive Treatment in Masked Hypertension

Antihypertensive Treatment in Masked Hypertension for Target Organ Protection (ANTI-MASK)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 320 (actual)
• Sponsor: Yan Li · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria). Improvement was defined as the relevant parameter back to normal or declined at least 20%. The secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).

Conditions

• Masked Hypertension

Interventions

Type	Name	Description
DRUG	Allisartan Isoproxil	Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
DRUG	Placebo	Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.

Timeline

• Start date: 2017-02-14
• Primary completion: 2021-10-30
• Completion: 2022-03-30
• First posted: 2016-09-08
• Last updated: 2025-01-06

Locations

1 site across 1 country: China